Bradmer to present poster on progression free survival and overall survival data from Neuradiab(TM) Phase II trials at Society for Neuro-Oncolo... (tibody 81c6. Each year up to 30000 ...)

HOME >> MEDICINE >> NEWS

Bradmer to present poster on progression free survival and overall survival data from Neuradiab(TM) Phase II trials at Society for Neuro-Oncology Meeting

Date:11/19/2008

tibody 81c6.

Each year up to 30,000 new cases of GBM are diagnosed in the world's seven largest healthcare markets. GBM tumors typically have infiltrating edges that are very difficult to completely remove with surgery. The Neuradiab therapy is delivered directly into the surgical resection cavity in a separate procedure after the initial surgery. Neuradiab delivers a concentrated level of radiation specifically to the remaining cancer cells by targeting tenascin. Tenascin is a protein over-expressed in 99% of GBM cells but absent from normal brain cells.

About Bradmer Pharmaceuticals Inc. (www.bradmerpharma.com)

Bradmer Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of new and innovative cancer therapies. Bradmer's lead clinical candidate, Neuradiab, was developed at Duke University Medical Center as a proprietary therapy for a particularly aggressive form of brain cancer, glioblastoma multiforme. Bradmer has initiated enrollment in a Phase III multi-center clinical trial of the licensed treatment. Neuradiab has been granted Orphan Drug Status by both the U.S. Food and Drug Administration and the European Medicines Agency.

Bradmer Pharmaceuticals Inc.'s common shares have not been registered under the Securities Act of 1933, as amended (the "Securities Act") or any state regulatory agency in the United States. The resale or transfer by a U.S. investor of such common shares of Bradmer Pharmaceuticals Inc. is subject to the requirements of Rule 904 of Regulation S of the Securities Act or such other applicable exemption thereunder, and other applicable state securities laws.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking
'/>"/>

0

GOOD

Page: 1 2 3 4
Related medicine news :

1. Bradmer announces 2008 third quarter operational and financial results
2. Bradmer to present at Rodman & Renshaw Healthcare Conference
3. Bradmer receives FDA approval to proceed with Phase III clinical trial
4. Bradmer announces 2008 first quarter operational and financial results
5. Bradmer announces new additions to management team
6. Bradmer announces 2007 fourth quarter and fiscal year operational and financial results
7. Notice of Bradmer Pharmaceuticals Conference Call
8. Bradmer announces Phase II results published in newly diagnosed glioblastoma which demonstrate improved survival and support upcoming Phase III study
9. Bradmer to present at the 10th Annual BIO CEO & Investor Conference
10. Bradmer announces additions to Scientific Advisory Board
11. Bradmer Medical Isotope Supply For Phase III Trial Secure

Post Your Comments:

Bradmer to present poster on progression free survival and overall survival data from Neuradiab(TM) Phase II trials at Society for Neuro-Oncolo...(tibody 81c6. Each year up to 30000 ...),Health